Lifemd, Inc. · NASDAQ:LFMD
Lifemd — Investor Presentation (May 2026)
26 slides from Lifemd's investor presentation, May 2026
Slide 1: Investor Presentation May 2026
Investor Presentation May 2026 NASDAQ: LFMD
Slide 2: Important Cautions Regarding Forward-Looking Statements
02 Important Cautions Regarding Forward-Looking Statements This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section 21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Priv
Slide 3: LifeMD is Transforming Care Delivery at Scale
03 LifeMD is Transforming Care Delivery at Scale Unique Monthly 453M+ Platform Interactions 365k+ Active Patients 1.95M+ Website Visitors End-to-end care Diversified portfolio Nationwide affiliated Integrated medical and Flexible, proprietary platform medical group pharmacy benefits technology stack Su
Slide 4: LifeMD Provides an End-to-End Destination for Virtual Care, Pharmacy, and Diagnostics
04 LifeMD Provides an End-to-End Destination for Virtual Care, Pharmacy, and Diagnostics Urgent Care Specialty Care On-demand video, audio, and Personalized programs serving men’s message-based consults with family and women’s health, cardiology, practitioners. diabetes, and psychiatry. Pharmacy Lab
Slide 5: LifeMD is Well Positioned to be a Leader in AI-enabled Virtual Care Delivery and Pharmacy
05 LifeMD is Well Positioned to be a Leader in AI-enabled Virtual Care Delivery and Pharmacy Our AI tools augment clinicians rather than replacing them, enabling higher throughput and consistency. Clinical Workflows Diagnosis & AI agents collect pre-consult data, transcribe consults, support revenue
Slide 6: LifeMD's Data, Infrastructure, and Platform Create a Durable AI Advantage
06 LifeMD’s Data, Infrastructure, and Platform Create a Durable AI Advantage End-to-End Tech-Enabled Experience Patient Base Delivers and optimizes the full patient Patient population that trusts journey—from discovery and intake to technology-enabled care models, and Large, highly structured data t
Slide 7: Our Affiliated Nationwide Medical Group Enables Scalable, High-Quality Care
07 Our Affiliated Nationwide Medical Group Enables Scalable, High-Quality Care 94% 2.4M 200+ General Wellness 4.8/5 Of consults start on time* Chronic Care Jan Weight management 26 Jan 26 at 11:00 am PST Different conditions Consults completed LifeMD treats Acute Care Average physician rating 98% 50
Slide 8: LifeMD's Nationwide Pharmacy Infrastructure Lowers Cost and Personalizes Care
08 LifeMD’s Nationwide Pharmacy Infrastructure Lowers Cost and Personalizes Care 50 State Direct-To-Patient Strategic Pharmaceutical AI-Enabled 503-A Pharmacy Collaborations Compounding LifeMD owns and operates a fully GLP-1 collaborations with 503-A compounding licensure licensed 50-state pharmacy
Slide 9: Nationwide Benefits Infrastructure Expands Access and Affordability
09 Nationwide Benefits Infrastructure Expands Access and Affordability ● Payer Contracting Today ● Provider Enrollment ● Real Time Benefit Verification 112M lives under coverage ● Prior Auth Submission & Appeals (82M commercial, 30M Medicare FFS) ● Out-of-Pocket Cost Estimates ● Medical Coding Q2 2026
Slide 10: The LifeMD Platform Targets Large, High-Impact Healthcare Markets
10 The LifeMD Platform Targets Large, High-Impact Healthcare Markets Our platform addresses the Concierge 500M visit care gap in the U.S. Primary Care Specialty Care 300M Women’s Health, Men’s Health, Weight, Cardiology, Psychiatry Primary & Urgent Care 100M Cold & Flu, Dermatology, Prescription Refi
Slide 11: Our management team has deep experience leading innovative healthcare organizations
11 Our management team has deep experience leading innovative healthcare organizations Justin Schreiber Atul Kavthekar Stefan Galluppi Shayna Dray Chief Executive Officer & Chief Financial Officer Chief Innovation Officer Chief Operating Officer Chairman Jessica Friedeman Eric Yecies Chris Pisano Nick A
Slide 12: Strategy
LifeMD* Strategy
Slide 13: LifeMD's High-Growth Care and Pharmacy Verticals
13 LifeMD’s High-Growth Care and Pharmacy Verticals Integrated virtual care and pharmacy services across primary and specialized health categories. GLP-1 Women’s Men’s Health Psychiatry Metabolic Health Health High margin, pharmacy driven Evidence-based virtual psychiatric Largest revenue and growth
Slide 14: Integrated Pharmacy Driving Margin Expansion
Integrated Pharmacy Driving Margin Expansion Vertically integrated, AI-enabled pharmacy platform delivering branded, generic, and personalized compounded therapies. ~90% gross margins in pharmacy operations. Personalized compounded formulations, where clinically appropriate, increase differentiation
Slide 15: Technology 50-State Benefits Infrastructure
15 Technology 50-State Benefits Jan 26 Weight management Jan 26 at 11:00 am PST Infrastructure Our proprietary platform connects triage, Robust medical and pharmacy benefits Jan Mental Health 11 Jan 11 at 09:00 pm PST Dec Women’s Health 24 Dec 24 at 07:00 am PST care, pharmacy, and analytics to enable
Slide 16: Weight Management
16 Weight Management 92,000+ active patients Large TAM; 100M Americans eligible, with fewer than 10% having tried therapy Strategic collaborations with Eli Lilly and Novo Nordisk Attractive historical unit economics Cross-care into specialized men's and women's health and cardiometabolic care
Slide 17: Women's Health
17 Women's Health 50% of U.S. counties lack an OB-GYN; 6,000+ women enter menopause daily Highly specialized provider group trained in midlife and hormone care National advisory board including Dr. Doug Lucas & Dr. Tara Scott Synchronous care, labs, diet & lifestyle, generic and compounded Rx
Slide 18: Men's Health
18 Men’s Health ~215,000 patients on therapy Asynchronous, pharmacy-driven business model Significant growth potential in personalized compounding Custom formulations launching for insomnia, anxiety, dermatology, and longevity Integration with NovoCare for Wegovy and Ozempic
Slide 19: Financials
LifeMD* miatelatersits
Slide 20: Our Brands Continue to Experience Rapid, Consecutive YoY Growth
20 Our Brands Continue to Experience Rapid, Consecutive YoY Growth Telehealth Revenue $225M $225M $155M $194M 2026E Revenue Forecast $98M 45% $68M $83M 5-Year Revenue CAGR $30M $11M 365k Active Patients 2019 2020 2021 2022 2023 2024 2025A 2026E 173% 127% 22% 18% 58% 25% 16% 2026 guidance represents
Slide 21: Rapid and Sustainable Profitability Growth in Our Core Telehealth Business
21 Rapid and Sustainable Profitability Growth in Our Core Telehealth Business Annual telehealth adjusted EBITDA ($ Millions) $15.3M $15.0M $3.7M 2024 2025A 2026E $(3.9)M $(20.0)M 2023 ($35.8)M 2022 2021 Note: adjusted EBITDA includes Telehealth only results. 2026 estimate based on midpoint of the cur
Slide 22: Rapidly Expanding Telehealth Gross Margins and Ad Spend Leverage
22 Rapidly Expanding Telehealth Gross Margins and Ad Spend Leverage Driven by Patient Retention are Driving Telehealth Profitability Growth Telehealth Gross Margin % Telehealth Ad Spend % of Revenue 90% 90% 80% 80% 70% 70% 60% 60% 50% 50% 40% 40% 30% 30% 20% 20% 10% 10% 0% 0% 2021 2022 2023 2024 2025
Slide 23: For FY'26, LifeMD Expects to Deliver the Following Metrics
23 For FY’26, LifeMD Expects to Deliver the Following Metrics: FY 2026 Q4 FY 2025 ACTUAL FY 2026 GUIDANCE Annualized Run Rate Telehealth Revenue $194.1 million $220 to $230 million $250 million Telehealth Adjusted $15.3 million $12 to $17 million $25 million EBITDA
Slide 24: Appendix
LifeMD* Appendix
Slide 25: Reconciliation of Net Income (Loss) to Adjusted EBITDA
25 Reconciliation of Net Income (Loss) Attributable to LifeMD, Inc. Common Stockholders to Adjusted EBITDA
Slide 26: Sources
Sources 26 A. Hersh, M. L. Stefanick, R. S. Stafford Trends in Hormone Therapy Use After the 2002 WHI Estrogen Plus Progestin Trial Medical Expenditure Panel Survey (MEPS), Agency for Healthcare Research and Quality (AHRQ), Statistical Brief #347: Use of Menopausal Hormone Therapy Drugs Among Women A